5-(4-氯苯在)噻吩-2-羧酸 | 40133-14-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 5-(4-氯苯在)噻吩-2-羧酸
• 英文名称: 5-(4-chlorophenyl)thiophene-2-carboxylic acid
• CAS: 40133-14-0
• 化学式: C₁₁H₇ClO₂S
• mdl: MFCD00206435
• 分子量: 238.694
• InChiKey: GWLCYLPZQKOCTB-UHFFFAOYSA-N

物化性质

• 熔点：
  254 °C
• 沸点：
  418.7±35.0 °C(Predicted)
• 密度：
  1.415±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  65.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 5-(4-Chlorophenyl)thiophene-2-carboxylic acid
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 5-(4-Chlorophenyl)thiophene-2-carboxylic acid
CAS number: 40133-14-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C11H7ClO2S
Molecular weight: 238.7

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  5-(4-氯苯在)噻吩-2-羧酸 在 六甲基磷酰三胺 、 lithium aluminium tetrahydride 、 氯化亚砜 、 硫酸 作用下， 以 四氢呋喃 、 乙醚 、 甲苯 为溶剂， 反应 7.0h， 生成 2-(Chloromethyl)-5-(4-chlorophenyl)thiophene
  参考文献：
  名称：

  Synthesis and structure–activity relationships of 5-phenylthiophenecarboxylic acid derivatives as antirheumatic agents

  摘要：

  5-(Phenylthiophene)-3-carboxylic acid (2a), a metabolite of esonarimod (1), which was developed as a new antirheumatic drug, was considered as a lead compound for new antirheumatic drugs. A new series of 2a derivatives were synthesized and their characteristic pharmacological effects, that is their antagonistic effect toward interleukin (IL)-1 in mice and the suppressive effect against adjuvant-induced arthritis (AIA) in rats, were evaluated and compared with those of 1. The structure-activity relationships indicated that [5-(4-bromophenyl)- thiophen-3-yl]acetic acid (5d), methyl [5-(4-chlorophenyl)-thiophen-3-yl]acetate acid (5d), and methyl [5-(4-bromophenyl)-thiophen-3-yl]acetate (5i) suppressed AIA more potently than 1 and all of the other synthesized compounds. (C) 2003 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2003.08.009
• 作为产物：
  描述：

  4-chlorocinnamaldehyde 在 sodium hydroxide 、 双氧水 、 碘 、 sodium acetate 作用下， 以 1,4-二氧六环 、 吡啶 、 溶剂黄146 为溶剂， 反应 30.0h， 生成 5-(4-氯苯在)噻吩-2-羧酸
  参考文献：
  名称：

  Campaigne, E.; White, R.L., Journal of Heterocyclic Chemistry, 1988, vol. 25, p. 367 - 373

  摘要：

  DOI：

文献信息

• Glutamate aggrecanase inhibitors
  申请人：Sum Phaik-Eng

  公开号：US20070043066A1

  公开（公告）日：2007-02-22

  The present invention relates to modulators of metalloproteinase activity.

  本发明涉及金属蛋白酶活性调节剂。
• Room-temperature cobalt-catalyzed arylation of aromatic acids: overriding the ortho-selectivity via the oxidative assembly of carboxylate and aryl titanate reagents using oxygen
  作者：Kun-Ming Liu、Rui Zhang、Xin-Fang Duan

  DOI：10.1039/c5ob02496j

  日期：——

  A room temperature phosphine or NHC ligand-free cobalt-catalyzed arylation of (hetero)aromatic acids has been developed.

  室温下，一种无需膦或NHC配体的钴催化的芳香酸（包括杂芳香酸）的芳香基化反应已经开发出来。
• [EN] ERR INVERSE AGONISTS<br/>[FR] AGONISTES INVERSES D'ERR
  申请人：UNIV SAINT LOUIS

  公开号：WO2019036562A1

  公开（公告）日：2019-02-21

  In one aspect, the present disclosure describes new estrogen receptor-related orphan receptor (EER) inverse agonist compounds. Also described are pharmaceutical formulations, methods of synthesis and uses thereof.

  在一方面，本公开描述了新的雌激素受体相关孤儿受体（EER）反向激动剂化合物。还描述了药物制剂、合成方法及其用途。
• Pharmaceutical compounds
  申请人：Lilly Industries Limited

  公开号：US04983619A1

  公开（公告）日：1991-01-08

  Compounds of the following formula have pharmaceutical properties: ##STR1## in which X is R'(HO)C.dbd.C(CN)--, R.sup.1 (CO)--CH(CN)-- or ##STR2## R.sup.1 and R.sup.2 are each hydrogen or C.sub.1-6 alkyl, R.sup.3, R.sup.4, R.sup.5 and R.sup.6 are each hydrogen, hydroxy, halogen, nitro, cyano, carboxy, C.sub.1-4 alkyl, C.sub.1-4 alkoxy, C.sub.1-4 alkylthio, halo-substituted C.sub.1-4 alkyl, halo-substituted C.sub.1-4 alkoxy, halo-substituted C.sub.1-4 alkylthio, C.sub.2-5 alkoxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, R'R"N-- where R' and R" are each hydrogen or C.sub.1-4 alkyl or R'"CONH-- where R'" is C.sub.1-4 alkyl, or a group of the formula --CR.sup.7 R.sup.8 R.sup.9 in which R.sup.7, R.sup.8 and R.sup.9 are each C.sub.1-6 alkyl, halo-substituted C.sub.1-6 alkyl or optionally substituted phenyl, or R.sup.7 and R.sup.8, together with the carbon atom to which they are attached, form a cycloalkyl group containing 3 to 7 carbon atoms, or R.sup.7, R.sup.8 and R.sup.9 together with the carbon atom to which they are attached, form a bicycloalkyl group containing 4 to 9 carbon atoms, and Y is a 5- or 6-membered heterocyclic ring excluding pyrazole; and salts thereof.

  以下化合物具有药理特性：##STR1## 其中X为R'(HO)C.dbd.C(CN)--，R.sup.1 (CO)--CH(CN)--或##STR2## R.sup.1和R.sup.2分别为氢或C.sub.1-6烷基，R.sup.3、R.sup.4、R.sup.5和R.sup.6分别为氢、羟基、卤素、硝基、氰基、羧基、C.sub.1-4烷基、C.sub.1-4烷氧基、C.sub.1-4烷硫基、卤素取代的C.sub.1-4烷基、卤素取代的C.sub.1-4烷氧基、卤素取代的C.sub.1-4烷硫基、C.sub.2-5烷氧羰基、可选择取代的苯基、可选择取代的苯氧基、R'R"N--其中R'和R"分别为氢或C.sub.1-4烷基或R'"CONH--其中R'"为C.sub.1-4烷基，或具有以下式--CR.sup.7 R.sup.8 R.sup.9的基团，其中R.sup.7、R.sup.8和R.sup.9分别为C.sub.1-6烷基、卤素取代的C.sub.1-6烷基或可选择取代的苯基，或R.sup.7和R.sup.8与它们连接的碳原子一起形成含有3至7个碳原子的环烷基，或R.sup.7、R.sup.8和R.sup.9与它们连接的碳原子一起形成含有4至9个碳原子的双环烷基，Y为排除吡唑的5-或6-成员杂环环，以及其盐。
• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS
  申请人：Washburn William N.

  公开号：US20080269110A1

  公开（公告）日：2008-10-30

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I where R 1 , R 1a , R 1b , A, R 3 , R 4 , R 5 , R5 b and R 6 are as defined herein.

  本申请提供了根据式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药用可接受形式。此外，本申请提供了含有至少一种根据式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据式I的化合物的治疗有效剂量。其中R1、R1a、R1b、A、R3、R4、R5、R5b和R6如本文所定义。